ALDX Share Price | Aldeyra Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Aldeyra Therapeutics, Inc. do?

Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on the identification and development of treatments for diseases related to high levels of aldehydes, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) Market cap: USD 185.08 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.17 Return on Equity: -90.72% Price to Book: 2.91Contact Details: Address: 131 Hartwell Ave Ste 320, LEXINGTON MA: 02421-3105 Tel: ['1 781 7614904', '1 857 3832409'] Fax: 1 302 6365454 Website: https://www.aldeyra.com/

Q: Is Aldeyra Therapeutics, Inc. technically bullish or bearish?

As of 20 August 2025, the technical trend for Aldeyra Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the KST is also bullish on both weekly and monthly time frames, indicating strong upward momentum. However, the weekly Dow Theory shows a mildly bearish stance, and the OBV is mildly bearish on the weekly but bullish on the monthly, suggesting some mixed signals. The moving averages are mildly bullish on the daily timeframe. In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.65% compared to the S&P 500's 17.14%, and a 5-year return of -32.57% versus the S&P 500's 96.61%. Overall, the current stance is bullish, but the strength is tempered by some conflicting indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

607.48 k

Shareholding (Sep 2025)

FII

2.95%

Held by 38 FIIs

DII

80.64%

Held by 21 DIIs

Promoter

0.52%

How big is Aldeyra Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Aldeyra Therapeutics, Inc. has a market capitalization of 185.08 million and reported net sales of 0.00 million with a net profit of -57.70 million over the last four quarters. Shareholder's funds were 71.00 million, and total assets were 104.61 million.

View full answer

What does Aldeyra Therapeutics, Inc. do?

22-Jun-2025

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for diseases associated with high aldehyde levels. It has a market cap of $185.08 million and reported a net profit loss of $10 million as of March 2025.

View full answer

Who are in the management team of Aldeyra Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Aldeyra Therapeutics, Inc. includes Dr. Richard Douglas (Independent Chairman), Dr. Todd Brady (CEO), and several independent directors: Dr. Ben Bronstein, Mr. Martin Joyce, Ms. Nancy Miller-rich, Dr. Gary Phillips, and Mr. Jesse Treu.

View full answer

Is Aldeyra Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 20, 2025, Aldeyra Therapeutics, Inc. shows a bullish trend with strong upward momentum indicated by the MACD and KST, despite mixed signals from Dow Theory and OBV, and has underperformed the S&P 500 over the past year and five years.

View full answer

Compare Aldeyra Therapeutics, Inc. with Similar Stocks

Lyell Immunopharma, Inc.Edgewise Therapeutics, Inc.Scholar Rock Holding Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 300 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.21

Return on Equity

-87.71%

Price to Book

6.10

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-23.11%

6 Months

-3.78%

1 Year

31.52%

2 Years

-54.1%

3 Years

42.58%

4 Years

-58.98%

5 Years

5.17%

Aldeyra Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-2.00%

EBIT to Interest (avg)

-28.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.17

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

63.74%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.51

EV to EBIT

-1.38

EV to EBITDA

-1.39

EV to Capital Employed

-7.62

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-90.72%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (15.87%)

Foreign Institutions

Held by 38 Foreign Institutions (2.95%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 41.67% vs -86.67% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.10",
          "val2": "-17.90",
          "chgp": "43.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.80",
          "val2": "-16.80",
          "chgp": "41.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -49.07% vs 39.52% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-59.90",
          "val2": "-42.50",
          "chgp": "-40.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "2.10",
          "chgp": "-9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.90",
          "val2": "-37.50",
          "chgp": "-49.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.10

-17.90

43.58%

Interest

0.50

Exceptional Items

0.00

Consolidate Net Profit

-9.80

-16.80

41.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 41.67% vs -86.67% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-59.90

-42.50

-40.94%

Interest

1.90

2.10

-9.52%

Exceptional Items

0.00

Consolidate Net Profit

-55.90

-37.50

-49.07%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -49.07% vs 39.52% in Dec 2023

All Annual Results

Company CV

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Company Coordinates

Company Details

131 Hartwell Ave Ste 320 , LEXINGTON MA : 02421-3105

Tel: 1 781 76149041 857 3832409

https://www.aldeyra.com/

Registrar Details

Aldeyra Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Aldeyra Therapeutics, Inc.?

Watch in Real-Time

What does Aldeyra Therapeutics, Inc. do?

Who are in the management team of Aldeyra Therapeutics, Inc.?

Is Aldeyra Therapeutics, Inc. technically bullish or bearish?

Compare Aldeyra Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Aldeyra Therapeutics, Inc.

Company Coordinates